Current use of PSMA–PET in prostate cancer management

Prostate-specific membrane antigen (PSMA) is a promising and specific target for prostate cancer imagingPSMA–PET imaging can add molecular information to multiparametric MRI and, therefore, delineate suspicious lesions for targeted biopsies, especially in patients whose biopsy samples are tumour-negativePSMA–PET imaging shows increased specificity and sensitivity compared with current standard imaging (CT, MRI and bone scintigraphy) in patients with primary intermediate-risk or high-risk prostate cancerPSMA–PET imaging improves detection of metastatic lesions even at low serum PSA values in biochemically recurrent prostate cancerEnhanced detection of prostate cancer lesions might enable improved patient-tailored therapy planning and, therefore, lead to improved therapy outcomes